COLLEGIUM PHARMACEUTICAL, INC (COLL) Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Collegium Pharmaceutical, Inc. NASDAQ:COLL Healthcare · Drug Manufacturers - Specialty & Generic
Mkt Cap $774.82M
Vol 0
$ Vol 0
RVOL 0
Earnings 0
Press Release
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Collegium Pharmaceutical expanded its partnership with Boston Legacy FC into a multi-year community program focused on neurodivergent children and families, including those with ADHD.
The deal adds Collegium branding to all Boston Legacy FC game kits and permanent press-box signage at White Stadium, plus a coaching certification initiative launching in 2027 through 2029 and an annual Sports for All Summit.
The partnership deepens Collegium's local presence ahead of its headquarters move to Boston in early 2027; no financial terms were disclosed, so near-term financial impact is negligible.
• 3d ago AI analysis › Press Release
Collegium to Report Third Quarter 2026 Financial Results on November 5, 2026
Collegium Pharmaceutical will report third quarter 2026 financial results before market open on Thursday, November 5, 2026.
A live conference call and webcast will follow at 8:00 a.m. ET, with a replay available on the company's website.
This is a scheduling notice only and contains no financial results or guidance.
• 10d ago AI analysis › Press Release
Collegium to Present Pediatric and Real-World Research Across ADHD Portfolio at AACAP and NEI Fall Congresses
Collegium Pharmaceutical announced that seven abstracts from its ADHD portfolio were accepted for presentation at the AACAP 2026 Annual Meeting (Oct 26-31, Atlanta) and the NEI Fall Congress (Nov 5-8, Colorado Springs).
The presentations include Phase 4 studies of AZSTARYS in pediatric populations and real-world analyses of JORNAY PM in adults, plus caregiver survey research; the real-world analyses are described as observational and hypothesis-generating.
No new clinical, regulatory, or financial data were disclosed — this is a scientific-congress visibility update supporting the company's marketed ADHD franchise.
• 11d ago AI analysis › Press Release
Collegium Launches "Start Talking ADHD" with Practical Support to Help Families Navigate Care, School and Everyday Life
Collegium Pharmaceutical launched Start Talking ADHD, an online resource hub with downloadable guides for patients, families, schools and providers.
The release contains no new financial, regulatory or pipeline information; it reinforces Collegium's ADHD franchise positioning, which added a second medicine in May 2026.
The company also highlighted its February 2026 partnership with Boston Legacy FC, including a sponsored sensory room at matches.
• 26d ago AI analysis › Press Release
Collegium to Participate in Upcoming Investor Conferences
Collegium Pharmaceutical announced its management will participate in two upcoming investor conferences in New York.
A fireside chat is scheduled at the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, followed by a presentation at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026.
Live webcasts and 90-day replays will be available via the investor relations section of Collegium's website; the notice contains no new financial or operating information.
• 1mo ago AI analysis › Press Release
Collegium Announces $50 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical entered into a $50 million Accelerated Share Repurchase agreement with Jefferies LLC, executing under its existing $150 million authorization.
The transaction involves an initial delivery of approximately 1.56 million shares based on the August 12 closing price of $25.70, with final settlement expected in the fourth quarter of 2026.
Management characterized the move as a compelling opportunity to create shareholder value, citing the company's strong cash generation and a belief that the current valuation does not reflect business strength.
• 2mo ago AI analysis › Press Release ⚠ 3
Collegium Reports Second Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium reported Q2 2026 revenue of $199.9 million, up 6% year-over-year, driven primarily by a 41% increase in JORNAY PM revenue to $46.1 million and the initial contribution of AZSTARYS following its May acquisition.
Despite the ADHD strength, the company cut its full-year 2026 guidance for Product Revenues to $825-$855 million and Adjusted EBITDA to $445-$470 million, citing lower net pricing on authorized generic versions of Nucynta.
The company generated $71.3 million in operating cash flow during the quarter and ended with $129.5 million in cash, while carrying $852.8 million in term notes and $238.7 million in convertible notes.
• 2mo ago AI analysis › Press Release
Collegium to Report Second Quarter 2026 Financial Results on August 6, 2026
Collegium Pharmaceutical announced it will report its second quarter 2026 financial results before the market opens on Thursday, August 6, 2026.
The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.
Collegium focuses on treatments for central nervous system and pain conditions, with a portfolio including ADHD medications JORNAY PM and AZSTARYS.
• 3mo ago AI analysis › Press Release
Collegium Pharmaceutical Announces New Corporate Headquarters at One Lincoln in Boston
Collegium Pharmaceutical plans to relocate its corporate headquarters to One Lincoln in downtown Boston during the first quarter of 2027.
CEO Vikram Karnani stated the move reflects the company's evolution and confidence in its future growth trajectory, while reinforcing its commitment to Massachusetts.
The new facility is owned by DivcoWest, with Avison Young serving as the real estate advisor for the site selection and lease negotiation.
• 3mo ago AI analysis › Press Release
Collegium Pharmaceutical Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Collegium Pharmaceutical awarded 50,305 restricted stock units to 34 newly hired non-executive employees.
The grants were issued under the company's 2026 Inducement Plan as a material inducement to employment, complying with Nasdaq Listing Rule 5635(c)(4).
The RSUs vest over three years, with one-third vesting on June 10, 2027, and the remainder in equal annual installments thereafter.
• 4mo ago AI analysis › Press Release
Collegium to Participate in 2026 Jefferies Global Healthcare Conference
Collegium Pharmaceutical announced that management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference.
The event is scheduled for Wednesday, June 3, 2026, at 1:20 p.m. ET in New York.
A live webcast will be available on the company's investor relations website, with a replay archived for 90 days.
• 5mo ago AI analysis › Press Release
Collegium Completes Acquisition of AZSTARYS® from Corium Therapeutics
globenewswire.com • 5mo ago Press Release ● Major
Collegium Reports First Quarter 2026 Financial Results and Highlights Recent Company Progress
Collegium reported Q1 2026 net revenue of $193.5 million, up 9% year-over-year, driven by a 36% increase in JORNAY PM revenue to $38.9 million.
The company is on track to close the $650 million acquisition of AZSTARYS in Q2 2026, which is expected to be immediately accretive and extend revenues into the late 2030s.
Management reaffirmed full-year 2026 guidance, including product revenues of $805-$825 million and Adjusted EBITDA of $455-$475 million.
• 5mo ago AI analysis › Press Release
Collegium to Report First Quarter 2026 Financial Results on May 7, 2026
Collegium Pharmaceutical announced it will report its first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
The company will host a conference call and webcast at 8:00 a.m. ET on the same day to discuss the results.
Collegium focuses on responsible pain management medications and neuropsychiatry, with JORNAY PM as its lead growth driver.
• 6mo ago AI analysis › 
